Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A Pilot, Randomized, Double-Blinded, Controlled Study of Hemodynamic and Acid Base Effects of 0.5M Sodium Lactate and 3% Saline Solutions in Septic Shock Patients
This study investigates two resuscitation fluids that are being used off label for the treatment of patients suffering from septic shock and also in patients with intracranial hypertension in intensive care.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | Experimental | Patients suffering from septic shock who require fluid resuscitation get 0.5M HSL (containing 504mM of sodium and lactate) |
|
| Group 2 | Active Comparator | Patients suffering from septic shock who require fluid resuscitation get 3% NaCl (containing 513mM of sodium and chloride) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sodium Lactate | Drug | 0.5M HSL (containing 504mM of sodium and lactate) |
|
| Measure | Description | Time Frame |
|---|---|---|
| haemodynamic effects | SV is the amount of blood that leaves the left ventricle with every beat cycle and is calculated by measuring the Doppler flow in the aortic valve. Unit: ml | at time of start of infusion, at 30 minutes and at 60 minutes from the start of the respective fluid bolus |
| Measure | Description | Time Frame |
|---|---|---|
| acid-base effect | Diagnostic approach to acid-base changes is based on the assessment of bicarbonate buffer system, in which pH is determined by the ratio of [HCO3-] to pCO2 meassured by a POC whole-blood analyzer system Unit: [HCO3-] - mmol/l, pCO2 - kPa | at time of start of infusion, at 30 minutes and at 60 minutes from the start of the respective fluid bolus |
Not provided
Inclusion Criteria:
Subjects will be eligible for the trial if they meet all of the following criteria:
Age criteria: 18 - 90 years
Septic shock - Sepsis 3 criteria :
Likely need for fluid resuscitation
Signed the relevant informed consent form
Exclusion Criteria:
Subjects will not be eligible for the trial if they meet any of the following criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Miroslav Kříž, MD | Contact | +420732850912 | krizm@fnplzen.cz | |
| Marek Nalos, MD | Contact | marek.nalos@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Pilsen | Recruiting | Pilsen | Czech Republic | 30100 | Czechia |
Not yet decided to sharing IPD.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012772 | Shock, Septic |
| D019586 | Intracranial Hypertension |
| ID | Term |
|---|---|
| D018805 | Sepsis |
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
Not provided
Not provided
| ID | Term |
|---|---|
| D019354 | Sodium Lactate |
| ID | Term |
|---|---|
| D007773 | Lactates |
| D006880 | Hydroxy Acids |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 3% NaCl | Drug | active compartor 3% NaCl |
|
| anti-inflammatory effect | Inflammatory markers as CRP, procalcitonin, interleukin-6 and feritin are sepcific indicators linked to degree of inflammation and determined by regular biochemical analysis. The dynamics of parameters after the study fluid administration will be evaluated. Unit: CRP - mg/l, procalcitonin - ug/l, interleukin-6 - ng/l, ferritin - ug/l | parameters measured within the last 24 hours prior to start of infusion and within 24 hours after the study fluid infusion. |
| Safety - Incidence of adverse events and reactions | Incidence of adverse events and reactions according to following Adverse Events of Special Interest (AESI) and descriptive analysis of the incidence of any adverse events and reactions during participation in the study in both study arms. AEs are defined according to the valid definitions for clinical trials as imposed by legislation (Directive 2001/20/EG). | 30 days after intervention |
| D010335 |
| Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012769 | Shock |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |